Key Highlights

  • Hikma Pharmaceuticals Plc (LSE:HIK) offers a Dividend Yield of 3.88% and now trades as a member of the FTSE 250 index.
  • The 2026 Interim Dividend was raised 6% to 38 cents per share from 36 cents.
  • The total dividend for 2025 was 84 cents per share, up 5%.
  • Operating cash flow rose 33% to US$214 million in the first half of 2026.
  • A US$250 million share buyback was well advanced, with US$227 million completed by 5 August 2026.

A Difficult Year Followed by Signs of Recovery

Hikma Pharmaceuticals Plc (LSE:HIK) has had a turbulent 2026. In February, the multinational generic and branded drugmaker issued 2026 guidance that fell short of market hopes and withdrew its medium-term targets following a strategic review of its Injectables business. The shares slumped, and in March FTSE Russell confirmed Hikma's demotion from the FTSE 100 to the FTSE 250, effective from 23 March.

Since then, the picture has improved. Interim results in August showed solid progress, the shares rose around 10% on the day, and the dividend continued to grow. With a dividend yield of 3.88%, LSE:HIK is now one of the higher-yielding healthcare names in the UK mid-cap space.

H1 2026 Results: Solid and Reassuring

Hikma reported group Revenue up 4% to US$1,728 million for the six months to 30 June 2026. Core operating profit increased 9% to US$405 million, core EBITDA rose 8% to US$463 million and core EPS improved 5% to 128 cents. Reported operating profit jumped 30% to US$336 million, largely because the prior-year period included a legal settlement charge.

Performance varied across divisions. Branded revenue grew 15% to US$502 million, with core operating profit up 23% and a Margin of 32.5%. Injectables revenue was flat at US$685 million, while core operating profit fell 8% as the company stepped up sales and Marketing Investment in the United States. Hikma Rx revenue was flat at US$520 million, but core operating profit rose 16%.

Chief Executive Said Darwazah said the company was encouraged by positive momentum and reiterated full-year guidance of 2% to 4% revenue growth in constant currency and core operating profit of US$720 million to US$770 million.

Dividend Growth and Capital Returns

The board declared an interim dividend of 38 cents per share, up 6% from 36 cents. Hikma declares dividends in US dollars, and UK shareholders receive the equivalent in sterling.

For the full year 2025, the total dividend was 84 cents, up 5% from 80 cents. Alongside the dividend, Hikma launched a US$250 million share buyback in February 2026, and by 5 August, US$227 million of shares had been repurchased. Together, the dividend and buyback represent a significant return of capital relative to the group's market value.

Payout Ratio and Dividend Cover

The 38 cent interim dividend represents roughly 30% of first-half core EPS of 128 cents, implying cover of more than three times. This conservative Payout Ratio leaves substantial room to sustain the dividend even if Earnings growth slows. The company's approach has been to grow the dividend steadily in line with underlying earnings while retaining capital for investment and acquisitions.

Cash Flow and Balance Sheet

Cash flow from Operating Activities increased 33% to US$214 million in the first half. Net Debt to core EBITDA rose to 1.9 times from 1.6 times at the end of 2025, reflecting the buyback and continued investment. That level of Leverage remains moderate for a pharmaceutical company with a diversified product portfolio. Hikma was upgraded to BBB by S&P and Fitch in 2025 and successfully refinanced a US$500 million Eurobond, supporting its access to funding.

Investment for Future Growth

Hikma increased Research and Development spending by 18% in the first half, made 48 product submissions and launched 43 new products. It also signed ten partnerships in the Middle East and North Africa region. Management believes these investments will underpin longer-term growth, particularly in Branded and in the US Injectables business, where it is working to strengthen its commercial platform.

Market Sentiment

Coverage from Reuters, financial news agencies and UK investment platforms following the interim results highlighted the stronger-than-feared performance and the reiterated guidance. The shares traded around 1,722p after the results, within a 52-week range of roughly 1,187p to 1,929p. On investor forums and social channels, sentiment has shifted from frustration over the FTSE 100 exit towards cautious optimism about a recovery.

Risks to the Dividend

The main risks include US generic drug pricing pressure, competition in injectables, regulatory and Manufacturing compliance issues, and geopolitical developments in the Middle East. Earlier in 2026, conflict in the region increased some costs. Currency movements also affect the sterling value of US dollar-denominated dividends.

Verdict: Is the 3.88% Yield Sustainable?

Hikma Pharmaceuticals Plc (LSE:HIK) offers a 3.88% dividend yield that appears well supported. The dividend is covered more than three times by core earnings, cash flow is improving and leverage remains moderate. The FTSE 250 demotion reflected disappointment over growth, not dividend safety. For income investors seeking defensive healthcare exposure with a growing payout and an active buyback, LSE:HIK merits attention.